Ignite Creation Date:
2024-05-06 @ 4:06 AM
Last Modification Date:
2024-10-26 @ 11:44 AM
Study NCT ID:
NCT02459288
Status:
UNKNOWN
Last Update Posted:
2015-06-02
First Post:
2014-09-23
Brief Title:
Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients
Sponsor:
Ping-Yen Liu
Organization:
National Cheng-Kung University Hospital
Study Overview
Official Title:
A comParison on Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Study Among SeVerE Chronic Kidney Disease End-Stage-Renal-Disease Patients With Recent Acute Coronary Syndrome
Status:
UNKNOWN
Status Verified Date:
2015-05
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
APROVE-CKD
Brief Summary:
A 4 week-duration cross-over study on Ticagrelor and Clopidogrel for the Acute Coronary Syndrome ACS and Chronic Kidney Disease CKD subjects focusing on the platelet inhibition and safety observation
Detailed Description:
Acute coronary syndrome is a high mortality and costly disease Antiplatelet therapies including aspirin and P2Y12 antagonist play important roles at the acute and subacute stage treatment for acute coronary syndrome especially after coronary stent implantation Patients with decreased estimated glomerular filtration rate eGFR experience higher cardiovascular morbidity and mortality Clopidogrel one of P2Y12 receptor antagonists inhibits the receptors activation by blocking its interaction with ADP However the efficacy of clopidogrel shows substantial variation and residual platelet reactivity which is related to adverse cardiovascular outcome especially in impaired renal function Our study aims to check the platelet inhibition rate comparing both medication with a cross-over study among CKD subjects and ACS condition
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None